Hetero Biopharma launched Derise (Darbepoetin Alfa) in Kenya – 2nd Commercial launch in Global Markets.
Hetero Biopharma – the Biologics arm of Hetero Group has recently launched ‘Derise’ (Darbepoetin Alfa) in Nairobi, the capital city of Kenya on 29th June 2017. Kenya is the 2nd market to launch Derise (Darbepoetin Alfa) commercially and Rilast (Rituximab), Bevaas (Bevacizumab) launches are expected shortly. Spearheaded by Mr. Krishna Kishore. AGM Global Biologics Business Development, Dr. Praveen Shetty - AGM, Global Clinical Strategy & Medico Marketing and Mr. Sudhir Phadke, Director Unisel Kenya Ltd – Hetero’s business partner in Kenya – the product Derise was launched in the presence of leading nephrologists. Mr. Phanindranath GM International Marketing, Mr. Manish Soni, Country Manager, Kenya and other marketing team of Unisel (K) Ltd were also present during the launch meeting cum CME.
This event served a great platform to launch Hetero Biopharma and its expertise in the area of Biosimilars. During this launch event, Dr. Praveen Shetty – AGM, Global Clinical Strategy and Medico Marketing made a presentation on ‘The role of Darbepoetin in CKD induced Anemia with African patients” to the doctors.
An exclusive training programme was also organized for the sales force of Kenya.
Gallery
